title: A comparative study of transdermal 10% lidocaine gel with and without glycyrrhetinic acid monohemiphthalate disodium for pain reduction at venous cannulation.
abstract: The clinical benefits of transdermal 10% lidocaine base gels with and without 3% glycyrrhetinic acid monohemiphthalate disodium (GAMHPh) for reduction of pain at venous cannulation were compared in a randomized, double-blind fashion in 24 surgical patients. After about 60 min of occlusive transdermal application, the mean pinprick pain score (1.3 +/- 1.5) in the GAMHPh group (n = 12), graded by noting the number of painful pinpricks out of five, was significantly less than that (2.5 +/- 1.7) in the control group (n = 12) (P less than 0.05). Twelve patients (eight in the GAMHPh group and four in the control group) who had a pinprick score less than 1 underwent venous cannulation without intradermal injection of a local anesthetic. The pain score at venipuncture, graded by the patients on a scale of 5, was significantly less in the GAMHPh group than that in the control group (1.9 +/- 1.1 vs 3.3 +/- 1.0, P less than 0.05). Erythema observed in 8 of the 24 patients was the only adverse local reaction. Addition of 3% GAMHPh to the lidocaine gel is useful in promoting transdermal lidocaine absorption.
authors.affiliation: Department of Anesthesiology, Kumamoto University Hospital, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kano
authors.forename: A
authors.initials: A
authors.lastname: Hashiguchi
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
authors.forename: T
authors.initials: T
authors.lastname: Morioka
authors.forename: M
authors.initials: M
authors.lastname: Mishima
authors.forename: M
authors.initials: M
authors.lastname: Nakano
mesh_terms: D000279:Administration, Cutaneous; D002406:Catheterization, Peripheral / Q000009:adverse effects*; D004311:Double-Blind Method; D005260:Female; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D012869:Skin Absorption / Q000187:drug effects
chemical_list: C064801:glycyrrhetinic acid 3-O-hemiphthalate; D008012:Lidocaine; D006034:Glycyrrhetinic Acid